ICCC Logo

ImmuCell Corporation (ICCC) 

NASDAQ
Market Cap
$32.88M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
562 of 775
Rank in Industry
303 of 433

Largest Insider Buys in Sector

ICCC Stock Price History Chart

ICCC Stock Performance

About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, …

Insider Activity of ImmuCell Corporation

Over the last 12 months, insiders at ImmuCell Corporation have bought $0 and sold $0 worth of ImmuCell Corporation stock.

On average, over the past 5 years, insiders at ImmuCell Corporation have bought $30,618 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,000 shares for transaction amount of $8,000 was made by Cunningham David () on 2022‑06‑13.

List of Insider Buy and Sell Transactions, ImmuCell Corporation

2022-06-13Purchase
1,000
0.0134%
$8.00$8,000-5.19%
2020-03-12Purchasedirector
2,000
0.0259%
$4.00$8,000+40.70%
2020-03-11Purchasedirector
4,600
0.0591%
$4.28$19,688+30.00%
2020-02-27Purchasedirector
5,130
0.0677%
$4.98$25,547+12.94%
2018-08-16Purchasedirector
3,000
0.0387%
$6.67$20,010+4.04%
2017-07-27Purchase
170,000
1.7068%
$5.25$892,500+6.81%
2017-07-27Purchase
30,000
0.3012%
$5.25$157,500+6.81%
2017-03-14Purchasedirector
1,197
0.0155%
$5.44$6,510+29.89%
2017-03-13Purchasedirector
803
0.0103%
$5.42$4,352+28.81%
2016-11-07Purchasedirector
4,000
0.0529%
$5.19$20,760+19.82%
2016-08-22Purchasedirector
3,000
0.0384%
$7.14$21,431-15.97%
2016-07-08SaleVP & Chief Scientific Officer
1,935
0.0242%
$6.55$12,669-10.22%
2016-07-07SaleVP & Chief Scientific Officer
265
0.0035%
$6.54$1,732-6.11%
2016-07-06SaleVP & Chief Scientific Officer
2,426
0.0313%
$6.59$15,979-7.81%
2016-07-05SaleVice President and CSO
2,600
0.0331%
$6.58$17,106-8.78%
2016-07-01SaleVice President and CSO
2,774
0.0373%
$6.88$19,095-8.18%
2016-03-21Purchasedirector
955
0.0126%
$6.67$6,370+1.61%
2016-01-29Purchase
9,522
0.1099%
$5.25$49,991+13.46%
2016-01-29Purchasedirector
6,666
0.077%
$5.25$34,997+13.46%
2016-01-29Purchasedirector
1,904
0.022%
$5.25$9,996+13.46%

Insider Historical Profitability

17.9%
ROTHSCHILD JONATHAN E
510158
5.7247%
$3.691070+21.25%
PESSIN NORMAN H
170000
1.9076%
$3.6910+6.81%
BRIGHAM MICHAEL FPresident & CEO
154870
1.7378%
$3.6950
CRABB JOSEPH HVP & Chief Scientific Officer
105111
1.1795%
$3.6955
Tomsche David Scottdirector
85519
0.9596%
$3.69280+13.65%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$1.15M2.77216,327+4.71%+$51,521.29<0.0001
Renaissance Technologies$662,000.001.6124,889-1.03%-$6,890.92<0.01
Cresset Asset Management Llc$549,112.001.33103,6060%+$0<0.01
Bleichroeder Lp$538,448.001.3101,5940%+$00.14
Morgan Stanley$342,995.000.8364,716-23.48%-$105,247.46<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.